A de novo novel missense mutation in AVPR2 with severe nephrogenic diabetes insipidus

Daisuke Kobayashi1, Shashi K. Nagaraj2, Jen-Jar Lin1 and Daniel G. Bichet3,*

1Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, NC, USA, 2Department of Pediatrics, Division of Pediatric Nephrology, Duke University School of Medicine, Durham, NC, USA and 3Genetics of Renal Diseases, Group d’étude des protéines membranaires, and Université de Montréal, Research Center and Nephrology Service, Hopital du Sacré-Cœur de Montréal, Montréal, Québec, Canada

Correspondence and offprint requests to: Daisuke Kobayashi; E-mail: dkobayas@wfubmc.edu

*Drs. Daniel G. Bichet and Jen-Jar Lin are joint senior authors.

Abstract

We describe a paediatric case of nephrogenic diabetes insipidus (NDI) with a novel mutation in the arginine vasopressin receptor 2 gene (AVPR2) in the absence of a family history of congenital polyuria. The patient, a 5-month-old Caucasian boy, had failure to thrive and hypernatraemia. On admission to hospital, he had a plasma sodium of 171 mEq/L with a concomittant urine osmolality of 131 mOsm/kg. Molecular genetic analysis demonstrated that the patient had an AVPR2 mutation (c.861C>G) resulting in a substitution of tryptophan for serine at amino acid position 167 (p.Ser167Trp). His mother was heterozygous for the same Ser167Trp mutation which was found to be de novo from the DNA analysis of the maternal grandparents.

Keywords: arginine vasopressin receptor 2; nephrogenic diabetes insipidus; S167W; X-linked recessive disease

Introduction

Nephrogenic diabetes insipidus (NDI) is a disorder characterized by renal insensitivity to arginine vasopressin (AVP). It is defined as the excretion of increased (typically >30 mL/kg/day) volumes of diluted urine (<250 mOsm/kg) [1]. About 90% of patients with congenital NDI are males with an X-linked recessive inheritance (OMIM 304800) of mutations in the arginine vasopressin receptor 2 gene (AVPR2) [1]. The gene is located in chromosomal region Xq28. The incidence of X-linked NDI was estimated to be ~8.8 per 100,000 live births in the Quebec region [2]. Spanakis et al. reported 211 AVPR2 gene mutations among symptomatic NDI in 326 families and 21 variants among asymptomatic NDI in 71 families [3]. Bichet et al. suggested that family members of the index cases with NDI should have their molecular defect identified since early diagnosis and treatment of affected infants can avert the physical and mental retardation which occurs as a result of repeated dehydration episodes [4].

Case report

A 5-month-old Caucasian boy was admitted to a community hospital for failure to thrive and hypernatraemia. His weight had decreased from the 10th percentile to below the 3rd percentile over a 1-month time period. His serum sodium was 171 mEq/L. He took 120–145 mL/kg/day of formula with 6–10 wet diapers daily. He was born at 36 weeks of gestation via induction delivery due to oligohydramnios. There was no perinatal stress. After birth, he was prescribed lansoprazole for gastroesophageal reflux. His mother was diagnosed with type 1 diabetes at 16 years of age.

His weight and height were 4.68 kg (below 3rd percentile) and 59.0 cm (below 3rd percentile), respectively. Serum sodium was 171 mEq/L, potassium 4.4 mEq/L, blood urea nitrogen 16 mg/dL, creatinine 0.3 mg/dL, albumin 4 g/dL and osmolality 348 mOsm/kg. Urine-specific gravity was 1.003 with an osmolality of 136 mOsm/kg. Daily urinary output was 1488 mL/day (5131 mL/m2/day). Renal ultrasound showed mild bilateral hydronephrosis.

His sodium increased to 180 mEq/L after fluid resuscitation with normal saline (NS), which subsequently failed to respond to three consecutive doses of desamino-arginine vasopressin (dDAVP) at 0.21 mcg/kg/dose or intravenous infusion of vasopressin at 111 milliunits/kg/h. His weight and height were 4.68 kg (below 3rd percentile) and 59.0 cm (below 3rd percentile), respectively. Serum sodium was 171 mEq/L, potassium 4.4 mEq/L, blood urea nitrogen 16 mg/dL, creatinine 0.3 mg/dL, albumin 4 g/dL and osmolality 348 mOsm/kg. Urine-specific gravity was 1.003 with an osmolality of 136 mOsm/kg. Urine sodium was <20 mEq/L. Daily urinary output was 1488 mL/day (5131 mL/m2/day). Renal ultrasound showed mild bilateral hydronephrosis.

His sodium increased to 180 mEq/L after fluid resuscitation with normal saline (NS), which subsequently failed to respond to three consecutive doses of desamino-arginine vasopressin (dDAVP) at 0.21 mcg/kg/dose or intravenous infusion of vasopressin at 111 milliunits/kg/h.

On admission, his blood pressure was 96/49 mm Hg with a heart rate of 188 beats/min. Serum sodium had decreased to 164 mEq/L. Intravenous administration of dDAVP at 0.21 mcg/kg during a water deprivation test (see Discussion) increased serum sodium from 167 to 173 mEq/L with signs of dehydration in one and half hours. Serum and urine osmolalities 1 h after the initiation of...
A de novo AVPR2 gene mutation

We describe a 5-month-old Caucasian boy with NDI due to a novel AVPR2 missense mutation with his mother being an asymptomatic heterozygous carrier. We determined that this novel AVPR2 mutation was a de novo mutation which occurred on the mother’s grandpaternal allele. In a previous study, 17 de novo AVPR2 mutations were identified in the mothers of affected boys and 16 mutations were inferred to occur during spermatogenesis [2]. The lack of family history of male family members affected with polyuria and polydipsia may delay the recognition of polyuric and dehydration signs and symptoms by the mother and may explain the delay in diagnosis seen with similar cases.

The phenotype due to this Ser167Trp mutation is severe because urine osmolality after water deprivation followed by DDAVP administration remained below 100 mOsm/kg with concomitant plasma sodium higher than 150 mEq/L. The water deprivation test with a baseline plasma sodium of 167 mEq/L was inappropriate and potentially dangerous since a strong indication for the diagnosis of NDI was already given by a plasma sodium of 171 mEq/L with a concomitant urine osmolality of 131 mOsm/kg. Also, the increase in plasma sodium observed after NS administration should be expected since a net gain of 100 mEq of Na⁺ will result from the infusion of 1 l of NS (150 mEq of Na⁺) and excretion of 1 l of dilute urine with a Na⁺ = 50 mEq. We do not have any specific explanation for the oligohydramnios observed here; pregnancies leading to the birth of infants subsequently found to have congenital sodium-losing nephropathies are often complicated by large polyhydramnios leading to repeated taps and prematurity but we know of no pregnancy leading to the birth of X-linked NDI children and complicated with a polydramnios. There is, however, one report of a patient with untreated central diabetes insipidus and oligohydramnios at 33 weeks gestation with resolution of the oligohydramnios after desmopressin [5], indicating that amniotic fluid volume may be affected by hydration. The mother was not polyuric at the time of the oligohydramnios but she did not have a 24-h urine volume evaluation. Some AVPR2 mutations (p.Asp85Asn, p.Val88Met, p.Gly201Asp and p.Pro322Ser) may be associated with a milder or partial phenotype and clinically important response to DDAVP and these ’milder’ mutations are associated with urine osmolalities >250 mOsm/kg [6,7].

The mutant protein Ser167Trp is likely misfolded since a full polyuric phenotype without a response of urine osmolality to dehydration or dDAVP is observed. Most of the AVPR2 mutations lead to mutant receptors that cannot reach the cell surface due to defective intracellular transport [1]. These misfolded vasopressin 2 receptor mutants could be rescued in vitro and in vivo by nonpeptide antagonists that function as pharmacologic chaperones [8].

The p.Ser167Trp is a novel mutation. In contrast, the p.Ser167Leu AVPR2 mutation reported in 14 apparently independent families was the largest case series among all the published mutations [3,9]. The p.Ser167Leu and p.Ser167Thr mutations have been expressed in COS.M6...
cells as misfolded and non-functional [10]. Other missense mutations affecting the same amino acid have been reported: p.Ser167Ala, p.Ser167Thr and p.Ser167Leu [3,9] as well as p.Ser167X [2]. The AVPR2 mutation at Ser167-Leu is considered a recurrent one since it occurs on different haplotypes [2].

The clinical differential diagnosis of this case was rather straightforward: this is a male with NDI with free-water loss from a non-inbred family, it was therefore indicated to sequence the AVPR2 gene. If an AVPR2 mutation was not identified, we would have sequenced the AQP2 gene searching for homozygous or compound heterozygous mutations [11]. Polyuric patients with prematurity, hypokalemia and a pregnancy history of polydramnios would suggest Bartter syndrome, but polyhydramnios during pregnancy has not been described in infants bearing AVPR2 or AQP2 mutations [12]. Familial hypomagnesemia with hypercalcemia (FHHNC) and nephronophthisis (NPHP) are also characterized by polydipsia and polyuria in early childhood. However, their polyuric phenotypes are less severe, as compared to that with AVPR2 or AQP2 mutations, and appear progressively after a few months of life with associated features such as hypomagnesemia, bilateral nephrocalcinosis, urinary tract infections and progressive renal failure in FHHNC and anaemia and renal failure in NPHP [13,14]. Patients with cystinosis are also polyuric although other phenotypic features of cystinosis are present. However, in infants, corneal opacity may be absent causing a delay in the diagnosis of cystinosis [15].

In conclusion, we encourage early clinical identification and molecular confirmation of all congenital polyuric and polydipsic cases.

**Conflict of interest statement.** None declared.

**References**

1. Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. *J Am Soc Nephrol* 2005; 16: 2836–2846

2. Arthus MF, Lonergan M, Crumley MJ et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus. *J Am Soc Nephrol* 2000; 11: 1044–1054

3. Spanakos E, Milord E, Gragnoli C. AVPR2 variants and mutations in nephrogenic diabetes insipidus: review and missense mutation significance. *J Cell Physiol* 2008; 217: 605–617

4. Bichet DG, Bimbauer M, Lonergan M et al. Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. *Am J Hum Genet* 1994; 55: 278–286

5. Hanson RS, Powrie RO, Larson L. Diabetes insipidus in pregnancy: a treatable cause of oligohydramnios. *Obstet Gynecol* 1997; 89: 816–817

6. Bichet DG, Fujiwara TM. Nephrogenic diabetes insipidus. In: CR Scriver, AL Beaudet, WS Sly (eds). *The Metabolic and Molecular Bases of Inherited Disease*. Vol. III, 8th edn. New York, USA: McGraw-Hill, 2001; 4181–4204

7. Bockenhauer D, Carpentier E, Rochdi D et al. Vasopressin type 2 receptor V88M mutation: molecular basis of partial and complete nephrogenic diabetes insipidus. *Nephron Physiol* 2009; 114: 1–10

8. Bernier V, Morello JP, Zarruk A et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. *J Am Soc Nephrol* 2006; 17: 232–243

9. Vaisbich MH, Carneiro J, Boson W et al. Nephrogenic diabetes insipidus (NDI): clinical, laboratory and genetic characterization of five Brazilian patients. *Clinics* 2009; 64: 409–414

10. Oksehe A, Schülein R, Rutz C et al. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function. *Mol Pharmacol* 1996; 50: 820–828

11. Guyon C, Lussier Y, Bissonnette P et al. Characterization of D150E and G196D aquaporin-2 mutations responsible for nephrogenic diabetes insipidus: importance of a mild phenotype. *Am J Physiol Renal Physiol* 2009; 297: F489–F498

12. Bichet DG. Hereditary polyuric disorders: new concepts and differential diagnosis. *Semin Nephrol* 2006; 26: 224–233

13. Konrad M, Hou J, Weber S et al. CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol* 2008; 19: 171–181

14. Hildebrandt F, Attanasio M, Otto E. Nephronophthisis: disease mechanisms of a ciliopathy. *J Am Soc Nephrol* 2009; 20: 23–35

15. Nesterova G, Gahl W. Nephropathic cystinosis: late complications of a multisystemic disease. *Pediatr Nephrol* 2008; 23: 863–878

Received for publication: 19.3.10; Accepted in revised form: 17.8.10